The latest price target for Protagonist Therapeutics (NASDAQ:PTGX) was reported by Citizens on May 6, 2026. The analyst firm set a price target for $137.00 expecting PTGX to rise to within 12 months (a possible 21.39% upside). 30 analyst firms have reported ratings in the last year.

The latest analyst rating for Protagonist Therapeutics (NASDAQ:PTGX) was provided by Citizens, and Protagonist Therapeutics maintained their market outperform rating.

There is no last upgrade for Protagonist Therapeutics

There is no last downgrade for Protagonist Therapeutics.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Protagonist Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Protagonist Therapeutics was filed on May 6, 2026 so you should expect the next rating to be made available sometime around May 6, 2027.

While ratings are subjective and will change, the latest Protagonist Therapeutics (PTGX) rating was a maintained with a price target of $120.00 to $137.00. The current price Protagonist Therapeutics (PTGX) is trading at is $112.86, which is out of the analyst’s predicted range.